RT Journal Article
SR Electronic
T1 A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP P166
DO 10.1186/2051-1426-3-S2-P166
VO 3
IS Suppl 2
A1 Weber, Jeffrey
A1 Grob, Jean-Jaques
A1 Margolin, Kim A
A1 Ascierto, Paolo A
A1 Sznol, Mario
A1 Ott, Patrick A
A1 Lejeune, Chantal
A1 de Pril, Veerle
A1 Ruisi, Mary M
A1 Hodi, F Stephen
YR 2015
UL http://jitc.bmj.com/content/3/Suppl_2/P166.abstract